DXCM:
Analysis & Opinions
-
November 15, 2012
Following the third quarter earnings release, we are maintaining our long-term 'Neutral' recommendation on DexCom ...
-
November 05, 2012
DexCom (DXCM), a player in the glucose monitoring market, reported third quarter 2012 loss per share of 25 cents, ...
-
August 27, 2012
We reiterate our Neutral recommendation on DexCom Inc. (DXCM). Its second-quarter 2012 loss per share of 21 cents ...
-
August 07, 2012
DexCom (DXCM), a player in the glucose monitoring market, reported second-quarter 2012 loss per share of 21 cents, ...
-
June 15, 2012
DexCom (DXCM), a player in the glucose monitoring market, recently reported that it received a CE Mark for its 4th ...
-
June 14, 2012
On June 13, Echo Therapeutics (ECTE), a transdermal medical device company, announced that it anticipates being ...
-
June 11, 2012
We remain Neutral on DexCom (DXCM). Its first-quarter 2012 loss per share of 21 cents exceeded the Zacks Consensus ...
-
March 09, 2011
DexCom shows that, although times are tough, people will still adopt better technology.
-
December 28, 2010
The year's top performers in a tough medical device sector.
-
December 08, 2010
In a surprise decision, an FDA panel votes to approve Contrave, Orexigen's new obesity drug.
-
November 09, 2010
2010 has been a rough year in the diabetes space.
-
July 07, 2010
These seven med-tech stocks are blazing a growth trail through their markets.
-
June 25, 2010
Gaining exposure to the micro-cap sector through ETFs and individual stocks.
-
January 25, 2010
The recent positive activity of these stocks points to strong investment potential.
